VivoSeq
Neurology

Spinocerebellar Ataxia Type 3

3

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

Spinocerebellar ataxia type 3 is an early-stage landscape with 3 programs across 3 companies. The most active players are Prism Pharmaceuticals, Solvay Pharmaceuticals, Liminal BioSciences Ltd..

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

75/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Prism Pharmaceuticals

1 program

Phase 2S

Solvay Pharmaceuticals

1 program

Phase 2L

Liminal BioSciences Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 23

Varenicline

Prism Pharmaceuticals

Lithium Carbonate

Solvay Pharmaceuticals

Sodium Benzoate

Liminal BioSciences Ltd.

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

4

clinical trials

Completed3 · 75%
Withdrawn1 · 25%

Clinical Trials

Trial Activity

Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3
Withdrawn·HHospital de Clinicas de Porto Alegre·Phase 2·NCT01096095
Chinese Medicine WT for Spinocerebellar Ataxia Type 3
Completed·—·Phase 2·NCT05038306·33 enrolled
Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3
Completed·HHospital de Clinicas de Porto Alegre·Phase 2/3·NCT01096082·62 enrolled
Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3
Completed·UUniversity of South Florida·Phase 2·NCT00992771·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)